| 产品名 | |||
| Omipalisib (GSK2126458, GSK458) | PI3K | 淋巴瘤,肺部疾病 | Phase 1 |
| Rigosertib (ON-01910.Na) | PLK | 胰腺癌,白血病 | Phase 3 |
| OSU-03012 (AR-12) | PDK-1 | 实体瘤,淋巴瘤 | Phase 1 |
| Momelotinib (CYT387) | JAK | 骨髓纤维化,血小板增多症 | Phase 3 |
| Danusertib (PHA-739358) | Aurora Kinase | 白血病 | Phase 2 |
| Amuvatinib (MP-470) | c-Kit | 肺癌 | Phase 2 |
| Lucitanib (E-3810) | FGFR | 胃食管反流病,消化性溃疡 | Phase 2 |
| Rociletinib (CO-1686) | EGFR | 肺癌 | Phase 3 |
| Volitinib (AZD6094) | c-Met | 肾细胞癌 | Phase 2 |
| AMG 337 | c-Met | 腺癌,胃癌 | Phase 2 |
| BMS-754807 | c-Met | 乳腺癌 | Phase 2 |
| Golvatinib (E7050) | c-Met | 头颈癌,肝细胞癌 | Phase 1/2 |
| Tepotinib (EMD 1214063) | c-Met | 肺癌 | Phase 2 |
| SAR125844 | c-Met | 肺癌 | Phase 2 |
| AP26113 | ALK | 肺癌 | Phase 3 |
| ASP3026 | ALK | 淋巴瘤 | Phase 1 |
| Ribociclib (LEE011 | CDK | 乳腺癌 | Phase 3 |
| Roniciclib (BAY1000394) | CDK | 肺癌 | Phase 2 |
| Niraparib (MK4827) | PARP | 乳腺癌,卵巢癌,输卵管癌 | Phase 3 |
| BMS-833923 (XL139) | Hedgehog/Smoothened | 基底细胞痣综合征 | Phase 2 |
| Taladegib (LY2940680) | Hedgehog/Smoothened | 肺癌,食管癌 | Phase 1/2 |
| RG-7112 (RO5045337) | Mdm2 | 白血病 | Phase 1 |
| Idasanutlin (RG-7388) | Mdm2 | 白血病,真性红细胞增多症 | Phase 3 |
